Last reviewed · How we verify

NCT07054398

Assessment of Serum Catestatin Level in Acne Vulgaris Patients

Recruiting now NA Last updated 8 July 2025
What this trial tests

NA trial testing Isotretinoin in Acne Vulgaris in 60 participants. Currently enrolling.

Timeline
10 January 2025
Primary endpoint
1 January 2026
10 January 2026

Quick facts

Lead sponsorAswan University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date10 January 2025
Primary completion1 January 2026
Estimated completion10 January 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Aswan University

Who can join

Adults 18 to 40, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Isotretinoin

Trials testing the same drug.

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

Other Aswan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07054398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing